RT Journal Article
T1 Enzyme-mediated synthesis of Molnupiravir: paving the way for the application of biocatalysis in pharmaceutical industry
A1 Cruz, Guillermo
A1 Acosta, Javier
A1 Del Arco, Jon
A1 Clemente Suarez, Vicente Javier
A1 Deroncele, Víctor
A1 Fernández Lucas, Jesús
AB Molnupiravir (Lagevrio®) is an orally-administered anti-COVID-19 agent. Due to the urgency to meet the worldwide demand and the growing environmental concern, there is a need for speed in the industrial implementation of novel and efficient bioprocesses for Molnupiravir synthesis. This concept paper aims to review the most relevant milestones that have guided important developments in the enzyme-mediated synthesis of Molnupiravir, including detailed comments on the advantages and drawbacks of the different synthetic routes. Finally, based on a personal perspective, new greener processes for Molnupiravir manufacturing are proposed and discussed.
PB Wiley-VCH
SN 1867-3880
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/108868
UL https://hdl.handle.net/20.500.14352/108868
LA eng
NO Cruz, Guillermo, et al. «Enzyme‐mediated Synthesis of Molnupiravir: Paving the Way for the Application of Biocatalysis in Pharmaceutical Industry». ChemCatChem, vol. 14, n.o 13, julio de 2022, p. e202200140. DOI.org (Crossref), https://doi.org/10.1002/cctc.202200140.
NO Ministerio de Ciencia e Innovación (España)
NO Fundación Banco Santander
DS Docta Complutense
RD 8 abr 2025